Dupixent Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high prevalence of atopic dermatitis and asthma, strong efficacy targeting il-4 and il-13, regulatory approvals across indications, specialist adoption, improved patient outcomes.

The growth in the forecast period can be attributed to expansion into new inflammatory conditions, rising biologics demand, increasing allergy and asthma incidence, broader reimbursement coverage, growing specialty pharmacy networks. Major trends in the forecast period include rising use in chronic inflammatory diseases, expansion across multiple indications, shift toward targeted biologic therapies, growth of long term maintenance treatment, increasing patient preference for injectable biologics.

The growing prevalence of skin allergies is anticipated to drive the expansion of the Dupixent market in the coming years. Skin allergies are immune system responses to certain substances that trigger skin irritation or inflammation, resulting in symptoms such as redness, itching, rashes, or swelling. The increase in skin allergies is associated with factors including rising environmental pollution, dietary changes, elevated stress levels, and greater exposure to allergens such as chemicals, fragrances, and harsh skincare products. Dupixent helps manage skin allergies by targeting and inhibiting specific immune pathways, particularly interleukin-4 and interleukin-13 signaling, which play a central role in inflammation, thereby alleviating symptoms such as itching, redness, and swelling while improving overall skin health and quality of life. For instance, in October 2023, according to the European Academy of Dermatology and Venereology (EADV), a Switzerland-based non-profit association, a survey of 44,689 adults across 27 European countries, including the EU, the UK, Norway, and Switzerland, reported that 43% of EU citizens experienced at least one skin condition in the previous year. The most frequently reported conditions included fungal skin infections, atopic dermatitis (eczema), alopecia, and acne. Therefore, the increasing prevalence of skin allergies is driving the growth of the Dupixent market.

The increase in healthcare expenditure is expected to further support the growth of the Dupixent market going forward. Healthcare expenditure refers to the total financial resources allocated to the delivery and use of healthcare services within a particular country or region. Rising healthcare spending is driven by factors such as an aging population, the growing burden of chronic diseases, advancements in medical technology, inflation, expanded access to healthcare services, and higher pharmaceutical and administrative costs. Increased healthcare expenditure supports Dupixent by enabling greater investment in innovative biologic therapies, improving access to advanced treatments for chronic conditions such as asthma and atopic dermatitis, and aligning with broader efforts to enhance patient outcomes and manage long-term healthcare costs effectively. For instance, in May 2024, according to the Office for National Statistics, a UK-based government agency, healthcare expenditure in the United Kingdom reached approximately $306 billion (£292 billion) in 2023, representing a 5.6% increase in nominal terms compared with 2022, significantly higher than the 0.9% growth recorded in the previous year. Therefore, rising healthcare expenditure is contributing to the growth of the Dupixent market.

Major companies operating in the Dupixent (dupilumab) market are increasingly focusing on expanding indications, such as broadening treatment options for type 2 inflammatory diseases, to strengthen their competitive position. Type 2 inflammatory diseases are conditions driven by an overactive type-2 immune response involving cytokines such as interleukin-4, interleukin-5, and interleukin-13. For instance, in March 2023, Sanofi S.A., a France-based biopharmaceutical company, received European Commission approval for Dupixent for use in infants aged 6 months to 5 years with severe atopic dermatitis, making it the first targeted biologic therapy approved for this age group. This approval highlights the treatment’s applicability across a broader patient population and supports its long-term value. However, the expansion of indications also presents challenges, as increased demand places pressure on production capacity, while broader clinical use requires more extensive clinical trials and heightened regulatory oversight.

Major companies operating in the dupixent market are Sanofi SA, Regeneron Pharmaceuticals Inc.

North America was the largest region in the dupixent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dupixent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dupixent market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the dupixent market by increasing costs related to biologic manufacturing inputs, prefilled injection devices, and cold chain logistics. These effects are particularly evident in specialty pharmacies and hospital distribution channels in Europe and Asia Pacific. Higher import duties have added pressure to treatment affordability for chronic inflammatory conditions. Supply chain planning has become more complex due to customs compliance. However, tariffs are encouraging regional biologics production and strengthening local specialty drug distribution infrastructure.

The dupixent market research report is one of a series of new reports that provides dupixent market statistics, including dupixent industry global market size, regional shares, competitors with a dupixent market share, detailed dupixent market segments, market trends and opportunities, and any further data you may need to thrive in the dupixent industry. This dupixent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dupixent is a prescription therapy used to manage a range of chronic inflammatory conditions, particularly in patients with moderate to severe disease manifestations. It is a monoclonal antibody that functions by blocking specific immune signaling proteins, namely interleukin-4 (IL-4) and interleukin-13 (IL-13), which are central to inflammatory and allergic responses. Dupixent is generally administered by injection, either subcutaneously or via a pre-filled pen.

The primary indications for Dupixent include atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Atopic dermatitis is a long-term inflammatory skin disorder marked by itching, redness, and dryness of the skin, often provoked by allergens or irritants. Dupixent is distributed through multiple channels, including hospital pharmacies, specialty pharmacies, and outpatient treatment centers.

The dupixent market consists of sales of antihistamines, immunosuppressants, oral antidiabetics, corticosteroids and blood coagulation modifiers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.